Tracy Staton

Biography for Tracy Staton

Tracy Staton, Senior Editor

Tracy Staton is the editor of FiercePharma and FiercePharmaMarketing. She has been a freelance writer for eight years, but before that served as editor of the Dallas Business Journal, editor of Texas Business magazine, and a senior editor at American Way, the inflight magazine of American Airlines. She is based in Vermont, and can be reached at tracy@fiercemarkets.com or find her on LinkedIn.

Articles by Tracy Staton

Most of pharma's 2014 woes playing out as execs expected

When surveyed about their outlook, pharma industry leaders said they felt plagued by uncertainty and beaten down by budget cuts. More than half worried they would receive pink slips by the end of this year. But some more optimistic execs predicted new investment in their departments, and many figured staffing levels will endure, at least for this year.

Celgene's cost-sharing offer persuades NICE to about-face on Revlimid

Celgene used a tried-and-true technique to persuade cost-effectiveness watchdogs to change their minds on Revlimid. The U.S.-based drugmaker capped its cost.

Lilly, Boehringer score FDA backing for Lantus copy, but patent fight awaits

Eli Lilly won't be able to sell its Lantus copycat--dubbed Basaglar--for at least 30 months because of a patent fight with Sanofi.

Big Pharma doesn't win the margin stakes. That's Jazz, Celgene, Regeneron and Alexion

Margins, margins, margins. That's an inevitable mantra among top investors and analysts. Just ask Novartis CEO Joe Jimenez, who's pledged big improvements in the Swiss drugmaker's spread. Or Eli Lilly CFO Derica Rice, who's had to explain why his company can promise to maintain margins as its sales spiral downward.

DOJ clears AstraZeneca for a U.S. Brilinta takeoff

The U.S. Department of Justice closed out its probe of a key Brilinta trial--and without further ado. No additional label warnings. And certainly no forced withdrawal from the U.S. market.

Biogen ready to steal market share with newly minted MS drug Plegridy

Biogen Idec has added another bow to its multiple sclerosis quiver. With the FDA's approval of Plegridy, a long-acting form of its popular Avonex, Biogen can fight for an even bigger share of the MS market.

Alabama Supreme Court redux: Pfizer can be sued for generic Reglan harms

The Alabama Supreme Court won't back away from a controversial ruling against Pfizer, in a liability case closely watched by the rest of the pharma industry.

The irrational rationale for cancer drug prices, with Novartis' Zykadia as exhibit A

Why do cancer drugs cost so much? We all know the stock answer--because companies need to recoup their development costs. Whether we believe it is something else, as Peter Bach of the Center for Health Policy and Outcomes writes in Forbes.

Communiqué to sales reps: With today's docs, it's the medium and the message

Almost half of doctors bar their doors to pharma sales reps some way, somehow. What with all the talk about rep access to physicians, that state of things may seem quote-unquote normal. But it's not. Just 6 years ago, the numbers were quite different.

The formularies are here! Brace yourselves for the 48 new exclusions

It started in 2011 with just a handful of drugs. CVS Caremark chucked 34 meds off its formulary, partly in a snit over copay coupons, partly just to see what would happen. Now, CVS' excluded list comprises almost 100 drugs and related products.